Safety, feasibility, and preliminary clinical outcomes of psilocybin-assisted therapy for veterans with severe, treatment-resistant PTSD: an open-label pilot clinical trial

This open-label pilot clinical trial (n=12) tested psilocybin-assisted therapy in U.S. military veterans with severe, treatment-resistant PTSD and found no serious side effects or increase in suicidal thoughts, while PTSD symptoms fell substantially over one month. Headache, anxiety and dizziness were the main non-serious adverse events.